

Supplementary Table 3.

MCED test sensitivity in alive or dead participants of cancer, listed by cancer type and clinical stage. Hazard ratio (HR) with 95% confidence interval and p-value across cancer types in all stages, stages I-III, and stage IV, for those with events in both MCED test detected and not detected groups were also indicated.

Cancers	Alive			Dead			HR (95% CI) Detected vs. Not Detected	p-value
	Total	Detected	Sensitivity (%)	Total	Detected	Sensitivity (%)		
Anus All	16	11	69	2	2	100	NA	NA
Stage I	4	2	50	NA	NA	NA	NA	NA
Stage II	7	4	57	NA	NA	NA	NA	NA
Stage III	5	5	100	1	1	100	NA	NA
Stage IV	NA	NA	NA	1	1	100	NA	NA
Bladder All	9	5	56	5	4	80	2.22 (0.25-19.99)	0.48
Stage I	4	2	50	NA	NA	NA	NA	NA
Stage II	4	3	75	1	1	100	NA	NA
Stage III	1	0	0	3	3	100	NA	NA
Stage IV	NA	NA	NA	1	0	0	NA	NA
Breast All	329	108	33	17	14	82	9.85 (2.83-34.33)	< 0.001
Stage I	140	6	4	2	0	0	8.57 (2.39-30.74)	< 0.001
Stage II	147	63	43	8	7	88		
Stage III	34	31	91	4	4	100		
Stage IV	8	8	100	3	3	100	NA	NA
Cervix All	16	8	50	1	1	100	NA	NA
Stage I	11	3	27	NA	NA	NA	NA	NA
Stage II	3	3	100	NA	NA	NA	NA	NA
Stage III	2	2	100	1	1	100	NA	NA
Colon/Rectum All	131	96	73	41	38	93	4.08 (1.26-13.24)	0.019
Stage I	20	9	45	1	0	0	2.17 (0.47-10.09)	0.32
Stage II	28	19	68	4	4	100		
Stage III	47	35	74	7	6	86		
Stage IV	36	33	92	29	28	97	2.26 (0.31-16.62)	0.42

Esophagus All	38	28	74	32	31	97	8.33 (1.13-61.19)	0.037
Stage I	5	0	0	1	1	100	NA	NA
Stage II	8	4	50	5	5	100	NA	NA
Stage III	14	13	93	10	10	100	NA	NA
Stage IV	11	11	100	16	15	94	0.26 (0.032-2.18)	0.22
Gallbladder All	8	6	75	5	3	60	0.76 (0.126-4.55)	0.76
Stage I	2	1	50	2	0	0	0.97 (0.13-7.03)	0.98
Stage II	1	1	100	NA	NA	NA		
Stage III	2	1	50	2	2	100		
Stage IV	3	3	100	1	1	100	NA	NA
Head and Neck All	67	58	87	16	14	88	1.24 (0.28-5.46)	0.78
Stage I	9	8	89	NA	NA	NA	0.77 (0.086-6.88)	0.81
Stage II	16	12	75	1	1	100		
Stage III	17	16	94	4	3	75		
Stage IV	25	22	88	11	10	91	1.60 (0.20-12.57)	0.65
Kidney All	61	5	8	10	10	100	NA	NA
Stage I	47	0	0	NA	NA	NA	NA	NA
Stage II	5	1	20	NA	NA	NA	NA	NA
Stage III	5	2	40	NA	NA	NA	NA	NA
Stage IV	4	2	50	10	10	100	NA	NA
Liver/Bile-duct All	17	14	82	19	18	95	3.42 (0.45-25.87)	0.23
Stage I	6	4	67	NA	NA	NA	2.62 (0.32-21.09)	0.37
Stage II	3	3	100	5	4	80		
Stage III	5	4	80	4	4	100		
Stage IV	3	3	100	10	10	100	NA	NA
Lung All	181	94	52	186	166	89	4.88 (3.07-7.77)	< 0.0001
Stage I	75	12	16	9	4	44	3.77 (2.14-6.63)	< 0.0001
Stage II	19	11	58	15	12	80		
Stage III	50	42	84	53	46	87		

Stage IV	37	29	78	109	104	95	3.13 (1.27-7.68)	0.013
Lymphoid Leukemia All (Not Staged)	51	26	51	6	5	83	3.55 (0.41-30.70)	0.25
Lymphoma All	136	101	74	20	17	85	1.87 (0.55-6.39)	0.32
Stage I	22	7	32	NA	NA	NA	1.30 (0.35-4.81)	0.7
Stage II	35	29	83	4	3	75		
Stage III	29	23	79	8	6	75		
Stage IV	50	42	84	8	8	100	NA	NA
Melanoma All	6	2	33	2	2	100	NA	NA
Stage I	3	0	0	NA	NA	NA	NA	NA
Stage II	1	0	0	NA	NA	NA	NA	NA
Stage IV	2	2	100	2	2	100	NA	NA
Myeloid Neoplasm All (Not Staged)	5	0	0	NA	NA	NA	NA	NA
Other^a All	29	10	34	14	10	71	3.54 (1.11-11.33)	0.033
Stage I	9	3	33	2	1	50	9.779 (1.218-78.5)	0.0319
Stage II	5	1	20	2	2	100		
Stage III	8	3	38	5	5	100		
Stage IV	5	3	60	3	2	67	1.27 (0.11-14.56)	0.85
No Stage	2	0	0	2	0	0	NA	NA
Ovary All	45	34	76	9	9	100	NA	NA
Stage I	5	2	40	NA	NA	NA	NA	NA
Stage II	3	0	0	NA	NA	NA	NA	NA
Stage III	30	26	87	7	7	100	NA	NA
Stage IV	7	6	86	2	2	100	NA	NA
Pancreas All	33	23	70	88	81	92	2.35 (1.08-5.09)	0.031
Stage I	9	5	56	10	7	70	1.54 (0.64-3.70)	0.34
Stage II	8	6	75	12	10	83		
Stage III	8	5	62	16	15	94		
Stage IV	8	7	88	50	49	98	2.98 (0.41-	0.28

							21.67)	
Plasma Cell Neoplasm All	37	29	78	9	6	67	0.54 (0.14-2.20)	0.39
Stage I	12	7	58	2	1	50	0.54 (0.14-2.20)	0.39
Stage II	13	10	77	4	3	75		
Stage III	12	12	100	3	2	67		
Prostate All	252	20	8	7	6	86	64.12 (7.71-533.60)	< 0.001
Stage I	54	0	0	1	0	0	NA	NA
Stage II	158	6	4	NA	NA	NA	NA	NA
Stage III	26	4	15	NA	NA	NA	NA	NA
Stage IV	14	10	71	6	6	100	NA	NA
Sarcoma All	17	5	29	3	2	67	4.01 (0.36-44.28)	0.26
Stage I	3	2	67	NA	NA	NA	NA	NA
Stage II	5	0	0	NA	NA	NA	NA	NA
Stage III	5	1	20	NA	NA	NA	NA	NA
Stage IV	4	2	50	3	2	67	4.01 (0.36-44.28)	0.26
Stomach All	9	6	67	15	14	93	5.16 (0.67-39.80)	0.12
Stage I	2	1	50	1	0	0	3.66 (0.42-32.09)	0.24
Stage II	3	1	33	4	4	100		
Stage III	2	2	100	1	1	100		
Stage IV	2	2	100	9	9	100	NA	NA
Thyroid All	5	0	0	NA	NA	NA	NA	NA
Stage I	3	0	0	NA	NA	NA	NA	NA
Stage II	1	0	0	NA	NA	NA	NA	NA
Stage IV	1	0	0	NA	NA	NA	NA	NA
Urothelial Tract All	5	3	60	NA	NA	NA	NA	NA
Stage I	1	1	100	NA	NA	NA	NA	NA
Stage II	4	2	50	NA	NA	NA	NA	NA
Uterus All	110	25	23	9	6	67	6.90 (1.72-27.69)	0.0065
Stage I	98	17	17	6	3	50	4.76 (1.06-	0.041

Stage II	2	1	50	1	1	100	21.32)	
Stage III	8	6	75	NA	NA	NA		
Stage IV	2	1	50	2	2	100	NA	NA

^aOther includes brain, mesothelioma, orbit, penis, pleura, skin cancer (not basal cell carcinoma, squamous cell carcinoma, or melanoma), small intestine, testis, thymus, vagina, vulva, and unspecified.
NA: not applicable; CI: confidence interval.